Bristol-Myers’ checkpoint star Opdivo fails a PhIII study for glioblastoma
Bristol-Myers Squibb $BMY has had another setback on the checkpoint inhibition front, though this one they can take in stride.
Their big drug Opdivo …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
